Evidence map›Paper›PMID 37375488›Full record

ArticlePathogens (Basel, Switzerland)2023

Detection of Asymptomatic Mpox Carriers among High-Ri Men Who Have Sex with Men: A Prospective Analysis.

Roberto Rossotti, Daniele Calzavara, Massimo Cernuschi, Federico D'Amico, Anna De Bona, Roberto Repossi, Davide Moschese, Simona Bossolasco, Alessandro Tavelli, Camilla Muccini and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Mpox in children and adolescents and contact follow-up in school settings in greater Paris, France, May 2022 to July 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Roberto RossottiDepartment of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.ORCID 0000-0003-4965-8789
Daniele CalzavaraMilano Checkpoint, 20124 Milan, Italy.ORCID 0000-0002-9999-891X
Massimo CernuschiMilano Checkpoint, 20124 Milan, Italy.
Federico D'AmicoDepartment of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.ORCID 0000-0001-7825-4922
Anna De BonaMilano Checkpoint, 20124 Milan, Italy.
Roberto RepossiMilano Checkpoint, 20124 Milan, Italy.
Davide MoscheseMilano Checkpoint, 20124 Milan, Italy.
Simona BossolascoMilano Checkpoint, 20124 Milan, Italy.
Alessandro TavelliICONA Foundation, 20142 Milan, Italy.
Camilla MucciniMilano Checkpoint, 20124 Milan, Italy.
Giovanni MuléMilano Checkpoint, 20124 Milan, Italy.
Antonella d'Arminio MonforteDepartment of Infectious Diseases, ASST Santi Paolo e Carlo, 20142 Milan, Italy.ORCID 0000-0003-0073-1789
Ospedale San Paolo · ITSan Raffaele University of Rome · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITASST Fatebenefratelli Sacco · IT

Funding

Gilead Sciences (United States) Global Monkeypox Outbreak Emergency FundRelab Srl Provided point-of-care tests with no charge
6 · The paper itself

Abstract

Mpox is traditionally considered a zoonotic disease with endemic circulation in Africa, but the 2022-2023 outbreak reached an unprecedented high number of cases in non-endemic countries, so that it was declared a public health emergency of international concern. The reasons for this extensive global spread, characterized by sexual transmission amongst men who have sex with men (MSM), have not been fully clarified. The existence of asymptomatic carriers with viable viral shedding might be an explanation and is under-debated after retrospective studies suggested that infection without symptoms might have a prevalence of 6.5%. We aimed to prospectively assess the presence of mpox infection in asymptomatic high-risk MSM using HIV pre-exposure prophylaxis and living with HIV. We selected individuals with no signs of active infection nor suggestive symptoms in the previous 21 days. Eligible individuals collected oral and anal swabs to undergo point-of-care testing for mpox and completed a 21-days follow-up. Seventy-two individuals were enrolled, and none tested positive for mpox infection nor developed symptoms during follow-up. We selected a high-risk population with a significant history of sexual exposure, but we failed to detect any asymptomatic infection. This observation might have important consequences in terms of contact management and epidemic control.

Indexed as

asymptomatic infectionmpoxpoint-of-care testingPrEP

Identifiers

PMID37375488
PMCPMC10304703
OpenAlexW4379472837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.